Department of Radiation Oncology, Univesity of Michigan, Ann Arbor, Michigan, USA.
Adv Exp Med Biol. 2010;671:117-30. doi: 10.1007/978-1-4419-5819-8_10.
Neurodegenerative diseases comprise an important group ofchronic diseases that increase in incidence with rising age. In particular, the two most common neurodegenerative diseases are Alzheimer's disease and Parkinson's disease, both of which will be discussed below. A third, Huntington's disease, occurs infrequently, but has been studied intensely. Each of these diseases shares characteristics which are also generalizeable to other neurodegenerative diseases: accumulation ofproteinaceous substances that leads inexorably to selective neuronal death and decline in neural function. Treatments for these diseases have historically focused on symptomatic relief, but recent advances in molecular research have identified more specific targets. Additionally, stem cell therapy, immunotherapy and trophic-factor delivery provide avenues for neuronal protection that may alter the natural progression of these devastating illnesses. Upcoming clinical trials will evaluate treatment strategies and provide hope that translational research will decrease the onset of debilitating disability associated with neurodegenerative disease.
神经退行性疾病包括一组重要的慢性疾病,其发病率随着年龄的增长而增加。特别是,两种最常见的神经退行性疾病是阿尔茨海默病和帕金森病,下面将分别讨论这两种疾病。第三种是亨廷顿病,虽然发病率较低,但研究非常深入。这些疾病的共同特点是:蛋白质物质的积累,导致不可避免的选择性神经元死亡和神经功能下降。这些疾病的治疗历史上一直侧重于症状缓解,但最近分子研究的进展已经确定了更具体的靶点。此外,干细胞治疗、免疫疗法和营养因子传递为神经元保护提供了途径,可能改变这些毁灭性疾病的自然进程。即将进行的临床试验将评估治疗策略,并为转化研究提供希望,以减少与神经退行性疾病相关的致残性残疾的发生。